Joseph Flanagan's questions to Personalis Inc (PSNL) leadership • Q3 2024
Question
Joseph Flanagan, on for Dan Brennan, asked whether the sequential strength in the pharma business was driven entirely by Moderna, or if MRD and other profiling revenues also grew, and questioned the opportunity for growth before Medicare approval.
Answer
CFO Aaron Tachibana confirmed that while Moderna's accelerated PCV work was the primary driver of sequential pharma growth, revenue from the ImmunoID NeXT platform and biopharma MRD projects also increased. CEO Christopher Hall added that biopharma MRD adoption is gaining traction despite long buying cycles, and he anticipates strong revenue growth from these customers in 2025, prior to clinical reimbursement.